[Skip to Content]
[Skip to Content Landing]
February 14, 1977

Clinical Study of Ticrynafen: A New Diuretic, Antihypertensive, and Uricosuric Agent

Author Affiliations

From the Departments of Medicine, Veterans Administration Hospital and Georgetown University School of Medicine, Washington, DC.

JAMA. 1977;237(7):652-657. doi:10.1001/jama.1977.03270340038016

In a double-blind study, 20 hypertensive patients were randomly assigned to a six-week regimen of either ticrynafen or hydrochlorothiazide.

Blood pressure was significantly reduced with both medications, although most patients required an increase in dosage from 250 to 500 mg ticrynafen daily. Whereas the serum uric acid level rose moderately in the hydrochlorothiazide-treated patients, it fell strikingly to less than half of the pretreatment level in patients treated with ticrynafen. Body weight decreased slightly in both groups, as did serum potassium levels. Blood urea nitrogen and serum creatinine levels rose slightly in both groups. The magnitude of these changes was not significantly different between the two groups. Use of ticrynafen was well tolerated.

Ticrynafen appears to be a useful new antihypertensive agent because of its unique combination of diuretic, antihypertensive, and hypouricemic effects.

(JAMA 237:652-657, 1977)